Relative risk for individual and composite end points
| . | Relative risk (95% CI) . | P . |
|---|---|---|
| Recurrent or persistent CMV infection | 2.6 (1.2-5.8) | .01 |
| CMVD | 6.4 (0.8-49.2) | .03 |
| TRM | 2.4 (0.8-6.9) | .07 |
| Composite | ||
| Recurrent or persistent CMV infection or CMVD | 2.8 (1.3-6.3) | .004 |
| Recurrent or persistent CMV infection, CMVD, or TRM | 2.4 (1.3-4.5) | .002 |
| . | Relative risk (95% CI) . | P . |
|---|---|---|
| Recurrent or persistent CMV infection | 2.6 (1.2-5.8) | .01 |
| CMVD | 6.4 (0.8-49.2) | .03 |
| TRM | 2.4 (0.8-6.9) | .07 |
| Composite | ||
| Recurrent or persistent CMV infection or CMVD | 2.8 (1.3-6.3) | .004 |
| Recurrent or persistent CMV infection, CMVD, or TRM | 2.4 (1.3-4.5) | .002 |
Delayed recovery of CMV-specific CD8+ T cells (< 7 cells/μL in all blood samples during the first 65 days after transplantation) is a significant risk factor for CMV-related complications. CI indicates confidence interval.